Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

icate superior protection when compared to similar viral challenge studies for competitive vaccine designs currently in human clinical trials. We are therefore very excited about the potential for our vaccine."

Dr. McNally continued, "On the financial side, we continue to benefit from NIH/HVTN support of our human clinical trials and we are seeking additional government support to fund our internal research and development activities to expand the use of our technology against strains (clades) of the HIV virus affecting other areas of the globe. From December 2011 to March 2012, we raised a total of $2.7 million in equity capital to bolster our cash reserves."

Comment on Gilead Science's Truvada® Prevention SubmissionDr. McNally also commented on the recent news related to an advisory panel's recommendation that the FDA approve Gilead Science's submission of their anti-viral medication, Truvada, for prevention of HIV. "While any positive step towards the control of this deadly disease is greatly welcomed, we must continue the search for safe, cost-effective measures to prevent HIV transmission. The high cost of oral medications, patient compliance, and risk of medical side effects clearly suggest the best solution still lies with a preventive vaccine. GeoVax's preventive vaccine is considered a leading candidate for the version of the virus prevalent in North and South America, and Europe."

Financial ReviewGeoVax reported a net loss for the three months ended March 31, 2012 of $730,513, or $0.04 per share, based on 16.7 million weighted average shares outstanding. For the three months ended March 31, 2011, the Company reported a loss of $606,282, or $0.04 per share, based on 15.7 million weighted average shares outstanding.

The Company reported revenues of $854,063 for the three months ended March 31, 2012, related to its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institutes
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)...  Marta Rendon, MD, founder of the Rendon Center for ... FL and international key opinion leader in dermatology, was one of ... States to attend the international Aesthetic Experts Summit ... Here, at this gathering of over 600 physicians from 57 ... surgery experts from Asia and ...
(Date:11/24/2014)...  AiCure, an artificial intelligence company providing advanced ... ingestion, has announced the start of a major ... receiving medication as maintenance therapy for opioid addiction. ... have quadrupled in the last 15 years. Opioids ... cocaine and benzodiazepines combined. Overall, the economic cost ...
(Date:11/24/2014)... FRANCISCO, Calif. , Nov. 24, 2014  Rigel Pharmaceuticals, ... M. Gower is retiring from the board of directors ... and Raul Rodriguez , most recently serving as the ... of chief executive officer and join the board of directors.  ... Directors since 2005, will become chairman. Mr. Gower is expected ...
Breaking Medicine Technology:Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Can artificial intelligence solve the $55 billion problem of opioid abuse? 2Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3
... SHENZHEN, China, Dec. 28, 2010 /PRNewswire-Asia/ -- Winner Medical ... a leading manufacturer of medical dressings, medical disposables and ... China, today reported that a successful promotional event was ... Inc.") to promote PurCotton® brand and Natural™ trademark in ...
... 27, 2010 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... marketer of medical devices worldwide, today announced shareholder resolutions ... in Hong Kong on December 22, 2010. ... incumbent directors Ms. Joyce I-Yin Hsu and Mr. Wu ...
Cached Medicine Technology:Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 2Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 3Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 4
(Date:11/24/2014)... 2014 The typical American diet includes ... ingredients. Consistently consuming a diet high in calories and ... excess fat that typically accumulate around the internal organs ... ugly head in the form of love handles, beer ... the decision to rid themselves of the burden of ...
(Date:11/24/2014)... Dr. Michael Kettel , a leading ... on NBC to discuss egg freezing as a viable and ... in the news recently, with new company benefits at Facebook ... , “[The companies] see it as a way to ... hot path.” Says Dr. Kettel. , Up until a few ...
(Date:11/23/2014)... (PRWEB) November 24, 2014 For the ... and retailer, has launched a great promotion for many ... ). Customers can get the best choice with amazing ... shopping at Tidebuy.com. , It is easy to ... now. Besides that, this selection is also famous for ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Nearly ... heart attacks, strokes, deep vein thrombosis and other ... a federal multidistrict litigation (MDL) underway in the ... , Court documents updated on November 17th ... (JPML) show the filing of 259 lawsuits against ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 23, 2014 ... the market such as its significance, programs and ... globally and Chinese suppliers major market gamers in ... company information, item specifications, prospective, manufacturing value, and ... statistical research, the evaluation symbolizes the globally and ...
Breaking Medicine News(10 mins):Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4
... Isabelle Taylor, of St Annes, Lancs, a mobile phone two ... would end up constantly // sending text messages to her ... ‘repetitive strain injury’ and becoming the youngest person in Britain ... explains that she's constantly on the phone messaging. Stating that ...
... the people who are undergoing fertility treatment do not ... apprehensive // about the repercussions .In a survey carried out ... approximately 300 patients, it was observed that the patients ... of their bosses. The survey, done for ...
... of the University of Portsmouth and colleagues a large number ... food intakes because their parents believed that they are ... 54 per cent of a sample group of one-year-olds were ... such food items initiated an allergic reaction in them ...
... properties very close to insulin, bringing hope to the thousands of ... by DIA-B, a biotech company whose chairman is the former federal ... apply for a patent, so your guess is as good as ... Dr Wooldridge, 'The medical and commercial potential this represents would be ...
... by McGill University in Montreal it was found that vitamin ... // . The sun shine vitamin as it is called ... It was also found that pregnant women consuming too little ... Canada, US and Australia met in Toronto and discussed the ...
... that patients who come for emergency treatment at Victoria Hospital ... The emergency ward at the hospital is said to be ... of beds. This has been further worsened with one of ... the last four months. ,He hospital sources have ...
Cached Medicine News:Health News:Role of Vitamin D in Preventing Cancer 2Health News:Victoria Hospital In Bangalore is Lacking Beds In Emergency wards 2
... for the Quantitative Measurement ... S level based on ... Inhibition by STA© Analyzers. ... of Protein S; Human ...
Immuno-turbidimetric Assay for Antithrombin III Antigen. Suspension of microlatex particles coated with specific antibodies....
Enzyme Immunoassay of Protein C Antigenby ELISA Method, 96 tests...
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~8.8 moles/vial and bovine factorXa ~2.2 ...
Medicine Products: